GT BIOPHARMA, INC. Adjustments to Additional Paid in Capital, Fair Value
GT BIOPHARMA, INC. (GTBP) reported Adjustments to Additional Paid in Capital, Fair Value of $3.03 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket · last filed 2023-03-30
- GT BIOPHARMA, INC. adjustments to additional paid in capital, fair value for fiscal 2022 was $3.03M, a 1107.97% increase from fiscal 2021.
- GT BIOPHARMA, INC. adjustments to additional paid in capital, fair value for fiscal 2021 was $251.00K, a 97.10% decline from fiscal 2020.
- GT BIOPHARMA, INC. adjustments to additional paid in capital, fair value for fiscal 2020 was $8.64M.
| Period end | Adjustments to Additional Paid in Capital, Fair Value 12 month |
|---|---|
| 2022-12-31 | $3.03M 10-K · filed 2023-03-30 |
| 2021-12-31 | $251.00K 10-K · filed 2023-03-30 |
| 2020-12-31 | $8.64M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |